


## Tubulin polymerization-IN-26

<b>Cat. No.:</b>	HY-149020
<b>CAS No.:</b>	2490291-68-2
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>23</sub> N <sub>3</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	397.47
<b>Target:</b>	Microtubule/Tubulin; Apoptosis
<b>Pathway:</b>	Cell Cycle/DNA Damage; Cytoskeleton; Apoptosis
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Tubulin polymerization-IN-26 (compound 12h) can inhibit the polymerization of microtubulin by binding to the colchicine binding site of microtubulin with an IC <sub>50</sub> value of 4.64 μM. Tubulin polymerization-IN-26 can induce apoptosis and inhibit cell metastasis or migration, and can be used as a potential compound for lung cancer research <sup>[1]</sup> .																
<b>In Vitro</b>	<p>Tubulin polymerization-IN-26 (compound 12h) (0.27-30 μM, 48 hours) shows potent cytotoxic activity against lung cancer cells<sup>[1]</sup>.</p> <p>Tubulin polymerization-IN-26 (compound 12h) (0.1 μM, 0.25 μM, 0.5 μM, 24 hours) induces cell apoptosis in a dose-dependent manner by promoting ROS production in cells<sup>[1]</sup>.</p> <p>Tubulin polymerization-IN-26 (compound 12h) (0.1 μM, 0.25 μM, 0.5 μM, 24 hours) arrests the cell cycle in G2/M phase<sup>[1]</sup>.</p> <p>Tubulin polymerization-IN-26 (compound 12h) (0.1 μM, 0.25 μM, 0.5 μM, 24 hours) inhibits microtubule protein polymerization<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human non-small cell lung cancer A549, Human triple negative breast cancer MDA-MB-231, Mouse melanoma B16-F10, Human breast cancer BT-474, Mouse triple negative breast cancer 4 T1, Rat kidney epithelial cell line NRK-52E</td> </tr> <tr> <td>Concentration:</td> <td>0.27-30 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Showed cytotoxic activity against A549, MDA-MB-231, B16-F10, BT-474, 4 T1, NRK-52E with IC<sub>50</sub> value of 0.29 μM, 1.48 μM, 1.25 μM, 0.42 μM, 0.49 μM, 1.58 μM respectively.</td> </tr> </table> <p>Apoptosis Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human non-small cell lung cancer A549</td> </tr> <tr> <td>Concentration:</td> <td>0.1 μM, 0.25 μM, 0.5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Changed cell nucleus from normal form to micronucleus with the concentration increasing.</td> </tr> </table>	Cell Line:	Human non-small cell lung cancer A549, Human triple negative breast cancer MDA-MB-231, Mouse melanoma B16-F10, Human breast cancer BT-474, Mouse triple negative breast cancer 4 T1, Rat kidney epithelial cell line NRK-52E	Concentration:	0.27-30 μM	Incubation Time:	48 hours	Result:	Showed cytotoxic activity against A549, MDA-MB-231, B16-F10, BT-474, 4 T1, NRK-52E with IC <sub>50</sub> value of 0.29 μM, 1.48 μM, 1.25 μM, 0.42 μM, 0.49 μM, 1.58 μM respectively.	Cell Line:	Human non-small cell lung cancer A549	Concentration:	0.1 μM, 0.25 μM, 0.5 μM	Incubation Time:	24 hours	Result:	Changed cell nucleus from normal form to micronucleus with the concentration increasing.
Cell Line:	Human non-small cell lung cancer A549, Human triple negative breast cancer MDA-MB-231, Mouse melanoma B16-F10, Human breast cancer BT-474, Mouse triple negative breast cancer 4 T1, Rat kidney epithelial cell line NRK-52E																
Concentration:	0.27-30 μM																
Incubation Time:	48 hours																
Result:	Showed cytotoxic activity against A549, MDA-MB-231, B16-F10, BT-474, 4 T1, NRK-52E with IC <sub>50</sub> value of 0.29 μM, 1.48 μM, 1.25 μM, 0.42 μM, 0.49 μM, 1.58 μM respectively.																
Cell Line:	Human non-small cell lung cancer A549																
Concentration:	0.1 μM, 0.25 μM, 0.5 μM																
Incubation Time:	24 hours																
Result:	Changed cell nucleus from normal form to micronucleus with the concentration increasing.																

### Cell Cycle Analysis<sup>[1]</sup>

Cell Line:	Human non-small cell lung cancer A549
Concentration:	0.1 $\mu$ M, 0.25 $\mu$ M, 0.5 $\mu$ M
Incubation Time:	24 hours
Result:	Resulted in more G2/M phase cells production which percentage were 17.6%, 29% and 50.3%, corresponding to concentrations of 0.1 $\mu$ M, 0.25 $\mu$ M, and 0.5 $\mu$ M, respectively. Resulted in even fewer G0/G1 phase cells production which percentage were 41.1%, 21.2%, and 4.9%, corresponding to concentrations of 0.1 $\mu$ M, 0.25 $\mu$ M, and 0.5 $\mu$ M, respectively.

## REFERENCES

[1]. Kavitha Donthiboina et al. Synthesis and biological evaluation of substituted N-(2-(1H-benzo[d]imidazol-2-yl)phenyl)cinnamides as tubulin polymerization inhibitors. Bioorg Chem. 2020 Oct;103:104191.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA